Zynex Inc. ZYXI shares are trading higher on Tuesday, after the company raised its first-quarter and fiscal year 2020 guidance.
The company raised fiscal year 2020 sales guidance from $75-$80 million to $78-$83 million versus the $72.4 million estimate.
Zynex through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.
Zynex shares were trading up 11.82% at $5.59 on Tuesday at the time of publication. The stock has a 52-week high of $15.27 and a 52-week low of $4.75.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
